Corticosteroid in Uveitis


Corticosteroids form the mainstay of therapy for noninfectious uveitis. The anti-inflammatory and immunosuppressive action is mediated by controlling the protein synthesis both at cellular and molecular level. Corticosteroids in uveitis can be administered by topical, periocular, intravitreal, and oral routes. Long-term use of corticosteroids is associated with side effects such as hypertension, osteoporosis, hyperglycemia, Cushing’s syndrome, cataract, glaucoma, and others. Corticosteroid-sparing immunosuppressive agents form the next line of treatment in chronic, recurrent, and nonresponsive uveitis.


Cystoid Macular Edema Triamcinolone Acetonide Anterior Uveitis Triamcinolone Acetonide Posterior Uveitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Fauci AS. Clinical aspects of immunosuppression: use of cytotoxic agents and corticosteroids. Immunology. Philadelphia: WB Saunders; 1978.Google Scholar
  2. 2.
    Nussenblatt RB, Whitcup SM, Palestine AG. Uveitis: fundamentals and clinical practice. St. Louis: Mosby; 1996.Google Scholar
  3. 3.
    McGhee CN. Pharmacokinetics of ophthalmic corticosteroids. Br J Ophthalmol. 1992;76:681–4.PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Leopold IH, Maylath R. Intraocular penetration of cortisone and its effectiveness against experimental corneal burns. Am J Ophthalmol. 1952;42:1125–34.CrossRefGoogle Scholar
  5. 5.
    Schoenwald RD, Stewart P. Effect of particle size on ophthalmic bioavailability of dexamethasone suspensions in rabbits. J Pharm Sci. 1980;69:391–4.CrossRefPubMedGoogle Scholar
  6. 6.
    Awan MA, Agarwal PK, Watson DG, McGhee CN. Dutton. Penetration of topical and subconjunctival corticosteroids into human aqueous humour and its therapeutic significance. Br J Ophthalmol. 2009;93:708–13.CrossRefPubMedGoogle Scholar
  7. 7.
    Foster CS, Davanzo R, Flynn TE, McLeod K, Vogel R, Crockett RS. Durezol (Difluprednate Ophthalmic Emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. J Ocul Pharmacol Ther. 2010;26:475–83.CrossRefPubMedGoogle Scholar
  8. 8.
    Nozik RA. Periocular injection of steroids. Trans Am Acad Ophth Otol. 1976;76:695–704.Google Scholar
  9. 9.
    Helm CJ, Holland GN. The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol. 1995;120:55–64.CrossRefPubMedGoogle Scholar
  10. 10.
    Salek SS, Leder HA, Butler NJ, Gan TJ, Dunn JP, Thorne JE. Periocular triamcinolone acetonide injections for control of intraocular inflammation associated with uveitis. Ocul Immunol Inflamm. 2013;21(4):257–63.Google Scholar
  11. 11.
    Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110:681–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Habot-Wilner Z, Sallam A, Pacheco PA, Do HH, McCluskey P, Lightman S. Intravitreal triamcinolone acetonide as adjunctive treatment with systemic therapy for uveitic macular edema. Eur J Ophthalmol. 2011;21 Suppl 6:S56–61.CrossRefPubMedGoogle Scholar
  13. 13.
    Williams GA, Haller JA, Kuppermann BD, Blumenkranz MS, Weinberg DV, Chou C, Whitcup SM, Dexamethasone DDS Phase II Study Group. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol. 2009;147:1048–54.CrossRefPubMedGoogle Scholar
  14. 14.
    Lowder C, Belfort Jr R, Lightman S, Foster CS, Robinson MR, Schiffman RM, Li XY, Cui H, Whitcup SM, Ozurdex HURON Study Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129:545–53.CrossRefPubMedGoogle Scholar
  15. 15.
    Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T, Fluocinolone Acetonide Uveitis Study Group. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006;113:1020–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Arcinue CA, Cerón OM, Foster CS. A comparison between the fluocinolone acetonide (retisert) and dexamethasone (ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther. 2013;29:501–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, Sugar EA, Thorne JE. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology. 2011;118(10):1916–26.CrossRefGoogle Scholar
  18. 18.
    Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology. 2010;117:1436–41.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Slabaugh MA, Herlihy E, Ongchin S, van Gelder RN. Efficacy and potential complications of difluprednate use for pediatric uveitis. Am J Ophthalmol. 2012;153:932–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Say EA, Shields CL, Bianciotto C, Shields JA. Perilymphatic subcutaneous fat atrophy and cutaneous depigmentation after periocular triamcinolone acetonide injection in a child. J AAPOS. 2011;15:107–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Jonas JB, Kamppeter BA. Intravitreal triamcinolone acetonide and central serous chorioretinopathy. Br J Ophthalmol. 2005;89:386–7.PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Malclès A, Janin-Manificat H, Yhuel Y, Russo A, Agard E, El Chehab H, Ract Madoux G, Masse H, Burillon C, Dot C. Anterior chamber migration of intravitreal dexamethasone implant (Ozurdex®) in pseudophakic eyes: report of three cases. J Fr Ophtalmol. 2013;36:362–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Bansal R, Bansal P, Kulkarni P, Gupta V, Sharma A, Gupta A. Wandering Ozurdex(®) implant. J Ophthalmic Inflamm Infect. 2012;2:1–5.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Ufret-Vincenty RL, Singh RP, Lowder CY, Kaiser PK. Cytomegalovirus retinitis after fluocinolone acetonide (Retisert) implant. Am J Ophthalmol. 2007;143:334–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Ramaiya KJ, Rao PK. Herpetic necrotizing retinitis following fluocinolone acetonide intravitreal implant. Ocul Immunol Inflamm. 2011;19:72–4.CrossRefPubMedGoogle Scholar
  26. 26.
    Sims JL, Chee SP. Cytomegalovirus endotheliitis following fluocinolone acetonide (Retisert) implant. Eye. 2010;24:197–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Rofagha S, Prechanond T, Stewart JM. Late spontaneous dissociation of a fluocinolone acetonide implant (Retisert). Ocul Immunol Inflamm. 2013;21:62–3.CrossRefGoogle Scholar
  28. 28.
    Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, Stiehm ER, Tessler H, Van Gelder RN, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513.CrossRefPubMedGoogle Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  1. 1.Senior Consultant, Department of Uveitis & Cornea ServicesSankara NethralayaChennaiIndia

Personalised recommendations